Dynavax Technologies (NASDAQ:DVAX) Stock Rating Upgraded by Wall Street Zen

Dynavax Technologies (NASDAQ:DVAX) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

DVAX has been the subject of a number of other reports. William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $15.38 on Friday. Dynavax Technologies has a 52 week low of $9.20 and a 52 week high of $15.49. The business’s 50 day moving average price is $11.10 and its 200 day moving average price is $10.58. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.81 billion, a P/E ratio of -41.57 and a beta of 0.89.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The company had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. On average, sell-side analysts expect that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Dynavax Technologies

Hedge funds have recently modified their holdings of the company. Hudson Bay Capital Management LP increased its stake in shares of Dynavax Technologies by 11.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 604,825 shares of the biopharmaceutical company’s stock valued at $6,006,000 after purchasing an additional 63,225 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Dynavax Technologies in the third quarter valued at approximately $109,000. Jacobs Levy Equity Management Inc. increased its position in shares of Dynavax Technologies by 1.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 118,484 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 1,610 shares in the last quarter. Verition Fund Management LLC increased its position in shares of Dynavax Technologies by 841.4% in the third quarter. Verition Fund Management LLC now owns 164,458 shares of the biopharmaceutical company’s stock valued at $1,633,000 after buying an additional 146,988 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of Dynavax Technologies by 163.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 754,041 shares of the biopharmaceutical company’s stock worth $7,488,000 after buying an additional 467,369 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.